
Oncology NEWS International
- Oncology NEWS International Vol 15 No 8
- Volume 15
- Issue 8
Normal Number of Melanocytes Defined
A Mayo Clinic physician and his colleagues have defined the normal number of melanocytes that are present in Caucasians' sun-exposed skin.
JACKSONVILLE, FloridaA Mayo Clinic physician and his colleagues have defined the normal number of melanocytes that are present in Caucasians' sun-exposed skin. Until now, there has not been a criterion to distinguish sun damage from early (in situ) melanoma. Lead author Ali Hendi, MD, and his team thought that pathologists and Mohs surgeons may err on the side of overdiagnosing melanoma in sun-damaged skin, leading to additional and unnecessary surgery, complications, or deformity. In the study, disease-free tissue samples were obtained from 149 randomly selected Caucasian patients undergoing Mohs surgery for nonmelanoma skin cancers of the face and neck (Arch Dermatol 142:871-876, 2006). They found that in normal sun-exposed skin, the mean number of melanocytes in a 0.5 mm diameter was 15.6 (range, 6 to 29). Adjacent melanocytes, another indicator used by pathologists to diagnose early melanoma, were present in varying degrees in all but 11% of the samples. Finally, melanocytes were found to descend along the hair follicles, a finding previously attributed only to melanoma in sun-damaged skin. Dr. Hendi said the findings are significant because many surgeons remove tissue until they reach undamaged cells with "normal" melanocyte distribution.
Articles in this issue
over 19 years ago
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcomeover 19 years ago
Triple Targeted Therapy Is Tested in Pts With Solid Tumorsover 19 years ago
FDA Approves Three-Drug Combination Tablet for HIV-1over 19 years ago
Side Effects Persist 16 Years After Prostate Ca Brachytherapyover 19 years ago
No Significant QOL Differences for Raloxifene and Tamoxifenover 19 years ago
Amrubicin Appears Promising in Small-Cell Lung Cancerover 19 years ago
R-MP Active in Older Pts With Newly Diagnosed Myelomaover 19 years ago
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trialsover 19 years ago
Takeda Signs Agreement With Galaxy Biotech for HuL2G7Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































